СПИСОК ЛИТЕРАТУРЫ

1. Аркадьева Г.В., Радзевич А.Э. Длительная терапия варфарином у больных с мерцательной аритмией без поражения клапанов сердца с целью профилактики тромбоэмболических осложнений // Рос.

2. Баркаган З.С., Момот А.П., Тараненко И.А. Основы пролонгированной профилактики и терапии тромбоэмболий антикоагулянтами непрямого действия (показания, подбор доз, лабораторный мониторинг): Методические указания. - М.: Ньюдиамед. 2003. 41 с.

3. Беленков Ю.Н., Оганов Р.Г. Кардиология. Национальное руководство. - М.: ГЭОТАР-Медиа. 2010. 1286 с.

4. Бойцов С.А., Подлесов А.М., Егоров Д.Ф. Мерцательная аритмия. - СПб.: Элби-СПБ. 2001. 335 с.

5. Верещагин Н.В. Гетерогенность инсульта в клинической практике //Атмосфера. Нервные болезни. 2004. №1. С. 19-20.

6. Гиляров М. Ю., Магомадова М. У, Генерозов Э. В., Морошкина С. Ю., Погода Т. В., Костин П. А., Сулимов В. А., Сыркин А. Л. Алгоритм подбора дозы варфарина с учетом носительства полиморфизмов генов цитохрома CYP2C9 и субъединицы 1 витамин К эпоксидредуктазы // Вестн. аритмологии. 2011. № 63. С. 28-31.

7. Глебов М.В. Ишемический инсульт, парадоксальная церебральная эмболия и открытое овальное окно: автореф. дис. ... канд. мед. наук. - М.: Научн. центр неврологии РАМН. 2009. 30 с.

8. Джанашия П.Х., Шогенов З.С. Основные причины и принципы лечения фибрилляции предсердий // Медицинский вестник. 2005. № 26. С. 34-45.

9. Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК и ВНОА, 2011. // ВНОК. 2011. С 1-84.

10. Диагностика и лечение фибрилляции предсердий: Российские рекомендации / Разраб. Комитетом экспертов Всерос. науч. о-ва кардиологов // Кардиоваскулярная терапия и профилактика. 2005. № 4. Прил. 2. 28 с.

11. Егоров Д.Ф., Лещинский Л.А., Недоступ А.В., Тюлькина Е.Е. Мерцательная аритмия: стратегия и тактика лечения на пороге XXI века.

12. Затейщиков Д.А., Зотова И.В., Данковцева Е.Н.. Сидоренко Б.А. Тромбозы и антитромботическая терапия при аритмиях. - М.: Практика. 2011. 264 с.

13. Кушаковский М.С. Аритмии сердца: руководство для врачей. - 3-е изд., испр. и доп. - СПб.: Фолиант. 2007. 672 с.

14. Кушаковский М.С. Фибрилляция предсердий (причины, механизмы, клинические формы, лечение и профилактика). - СПб.: Фолиант, 1999. 176 с.

15. Метелица В.И. Справочник по клинической фармакологии сердечно­сосудистых лекарственных средств. - М.: Бином. 2002. 925с.

16. Мироненко Т.В., Сорокин Ю.Н., Бахтояров П.Д. Актуальные вопросы ангионеврологии. - Луганск: б.и.. 2008. 326 с.

17. Новикова Н.А., Сорокина Е.Г., Гиляров М.Ю., Саркисова Н.Д. Влияние гендерных факторов на характер антитромботической терапии у пациентов с фибрилляцией предсердий // Вестн. аритмологии. 2009. № 58. С. 21-24.

18. Сердечная Е.В. Фибрилляция предсердий: особенности клинического течения и выбор стратегии лечения: автореф. дис. ...д-ра мед. наук. - Архангельск: Северный государственный медицинский университет. 2008. 35 с.

19. Сердечная Е.В., Татарский Б.А., Истомина Т.А. Эпидемиология фибрилляции предсердий // Экология человека. 2009. Т. 11. C. 48-54.

20. Скворцова В. И., Стаховская Л.В., Айриян Н.Ю. Эпидемиология инсульта в Российской Федерации // Consilium Medicum. 2003. № 2-5, приложение 1.

С. 10-12.

21. Суслина З.А., Верещагин Н.В., Пирадов М.А. Подтипы ишемических нарушений мозгового кровообращения: диагностика и лечение // Consilium medicum. 2001. № 5. С. 218-221.

22. Суслина З.А., Танашян М.М. Антитромботическая терапия в ангионеврологии. - М.: Медкнига, 2004. 110 с.

23. Сыркин А.Л., Новикова Н.А., Терехин С.А. Острый коронарный синдром. - М.: МИА. 2010. 90 с.

24. Фонякин А. В., Суслина З. А., Гераскина Л. А. Кардиологическая диагно- стика при ишемическом инсульте. - СПб: ИНКАРТ. 2005. 224 c.

25. Фонякин А. В., Суслина З.А, Гераскина Л. А. Стратификация причин кар диоэмболического инсульта // Неврологический журн.

26. Шилов А.М., Мельник М.В., Осия А.О., Свиридова А.Ю., Мельник Н.В. Патофизиология и принципы лечения фибрилляции предсердий // Кардиология. 2011. № 14. С. 877-883.

27. Allen C.L., Bayraktutan U. Risk factors for ischaemic stroke // Int. J. Stroke.

2008. V. 3. P 105-116.

28. Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) // Chest. 2008. V 133 (suppl. 6). P 160S-198S.

29. Apostolakis S., Shantsila E., Lip GY, Lane D.A. Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation // Thromb. Haemost. 2009. V. 102. P 914-915.

30. Aring C.D., Merritt H.H. Differential diagnosis between cerebral hemorrhag and cerebral thrombosis // Arch. Intern. Med. 1935. V. 56. P 435-456.

31. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., Levy

D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study // Circulation. 1998. V. 98. P. 946-952.

32. Bogousslavsky J., Cachin C., Regli F., Despland P.A., Van Melle G., Kappenberger L. Cardiac sources of embolism and cerebral infarction-clinical consequences and vascular concomitants: the lausanne stroke registry // Neurology. 1991. V 41. P. 855-859.

33. Bunch T.J., Day J.D., Olshansky B., Stolen K.Q., Mullin C.M., INTRINSIC RV Study Investigators. Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality // Heart Rhythm. 2009. V. 6. P. 2-8.

34. Bunch T.J., May H.T., Bair T.L., Weiss J. P., Crandall B.G., Osborn J.S., Mallender C., Anderson J.L., Muhlestein B.J., Lappe D.L., Day J.D. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score // Heart Rhythm. 2013. V. 10. P. 1272-1277.

35. Caldeira D. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials // Arch. Cardiovasc. Dis. 2012. V. 105. P. 226-238.

36. Cameron A., Schwartz M. J., Kronmal R. A., Kosinski A.S. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry) // Am. J. Cardiol. 1988. V. 61. P. 714-717.

37. Camm A.J., Kirchhof P., Lip G.Y, Schotten U., Savelieva I., Ernst S., Van Gelder I.C., Al-Attar N., Hindricks G, Prendergast B., Heidbuchel H., Alfieri O., Angelini A., Atar D., Colonna P., De Caterina R., De Sutter J., Goette A., Gorenek

B. , Heldal M., Hohloser S.H., Kolh P., Le Heuzey J.Y, Ponikowski P., Rutten F.H. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) // Eur. Heart. J. 2010. V 31. P. 2369-2429.

38. Cleland J.G.F., Keshavarzi F., Pellicori P., Dicken B. Case Selection for Cardiac Resynchronization in Atrial Fibrillation // Heart Failure Clinics. 2013. V 9. P. 461-474.

39. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly P.A., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J., Diaz R., Lewis B.S., Darius H., Diener H.C., Joyner C.D., Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation // N. Engl. J. Med.

2009.V. 361. P 1139-1151.

40. Das R. R.,Seshadri S., Beiser A.S., Kelly-Hayes M., Au R., Himali J.J., Kase

C. S., Benjamin E.J., Polak J.F., O'Donnell C.J., Yoshita M., D'Agostino R.B. Sr, DeCarli C., Wolf P.A. Prevalence and Correlates of Silent Cerebral Infarcts in the Framingham Offspring Study // Stroke. 2008. V. 39. P. 2929-2935.

41. Davis S.N., Donnan G.A. Clinical practice. Secondary prevention after ischemic stroke or transient ischemic attack // N. Engl. Med. 2012. V. 366. P. 1914-1922.

42. Djousse L., Pankow J.S., Arnett D.K., Eckfeldt J.H., Myers R.H., Ellison R.C.

43. Donnan GA., Fisher M., Macleod M., Davis S.M. Stroke // Lancet. 2008. V. 371. P 1612-1623.

44. Doufekias E., Segal A.Z., Kizer J.R. Cardiogenic and aortogenic brain embolism // J. Am. Coll. Cardiol. 2008. V. 51. P 1049-1059.

45. Dries D.L., Exner D.V, Gersh B.J., Domanski M.J., Waclawiw M.A., Stevenson L.W. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials // J. Am. Coll. Cardiol. 1998. V 32. P 695-703.

46. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation and transient ischaemic attack or minor stroke // Lancet. 1993. V 342. P 1255-1262.

47. Eagle K.A., Cannom D.S., Garcia D.A. Management of atrial fibrillation: translating clinical trial data into clinical practice // Am. J. Med. 2011. V. 124. P. 4-14.

48. Eldar M., Canetti M., Rotstein Z., Boyko V., Gottlieb S., Kaplinsky E., Behar S. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups // Circulation. 1998. V 97. P 965-970.

49. Ellenbogen K.A., Tan A.Y Comparing the Imperfect with the Imperfect: The Imprecise Science of Assessing the Risk and Benefits of Anticoagulation in Atrial Fibrillation // Circulation. 2014. V. 129. P. 1997-1999.

50. ESC Guidelines. Guidelines for the management of atrial fibrillation. // Eur. Heart J. 2010. V 31. P. 2369-2429.

51. Feigin VL., Lawes C.M.M., Bennett D.A., Anderson C.S. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century // Lancet Neurol. 2003. V.

52. Feinberg W.M., Blackshear J.L., Laupacis A., Kronmal R., Hart R.G Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications // Arch. Intern. Med. 1995. V. 155. P. 469-473.

53. Flaker G.C., Belew K., Beckman K., Vidaillet H., Kron J., Safford R., Mickel M., Barrell P. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study // Am. Heart. J. 2005. V 149. P. 657-663.

54. Friberg J., Scharling H., Gadsboll N., Jensen G.B. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study) // Am. J. Cardiol. 2003. V 92. P. 1419-1423.

55. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation // Eur. Heart J. 2010. V. 31. P. 967-975.

56. Furberg C.D., Psaty B.M., Manolio T.A., Gardin J.M., Smith V.E., Rautahariu P.M. The prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study) // Am. J. Cardiol. 1994. V 74. P. 236-241.

57. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., Halperin J.L., Le Heuzey J.-Y, Kay G.N., Lowe J.E., Olsson S.B., Prystowsky

E. N., Tamargo J.L., Wann S. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation // J. Am. Coll. Cardiol. 2006. V. 48. P. 854-906.

58. Giles M.F., Rothwell P.M. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis // Lancet Neurol. 2007. V 6. P. 1063-1072.

59. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., Singer

D. E. Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study // J. Am. Med. Assoc. 2001. V. 285. P. 2370-2375.

60. Goldberg R.J., Seeley D., Becker R.C., Brady P., Chen Z.Y, Osganian V., Gore

J.M., Alpert J.S., Dalen J.E. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community­wide perspective // Am. Heart J. 1990. V. 119. P. 996-1001.

61. Goldberg R.J., Yarzebski J., Lessard D., Wu J., Gore J.M. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective // Am. Heart J. 2002. V. 143. P 519-527.

62. Gorin L., Fauchier L., Nonin E., de Labriolle A., Haguenoer K., Cosnay P., Babuty D., Charbonnier B. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score =1 //Thromb. Haemost. 2009. V. 103. P. 833-840.

63. Hackam D.G, Spence J.D. Combining multiple approaches for the secondary prevention of vascular events alter stroke: a quantitative modeling study // Stroke. 2007. V. 38. P 1881-1885.

64. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation // Ann. Intern. Med. 2007. V 146. P. 857-867.

65. Hart R.G., Pearce L.A., Koudstaal PJ. Transient Ischemic Attacks in Patients With Atrial Fibrillation: Implications for Secondary Prevention: The European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III Trial // Stroke. 2004. V. 35. P. 948-951.

66. Hart R.G, Pearce L.A., Rothbart R.M., McAnulty J.H., Asinger R.W., Halperin J.L. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy: Stroke prevention in atrial fibrillation investigator // J. Am. Coll. Cardiol. 2000. V 35. P. 183-187.

67. Healey J.S. Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation // J. Thromb. Haemost. 2009. V. 102. P. 912-913.

68. Healey J.S., Connolly S.J., Gold M.R., Israel C.W., Van Gelder I.C., Capucci A., Lau C.P., Fain E., Yang S., Bailleul C., Morillo C.A., Carlson M., Themeles E., Kaufman E.S., Hohnloser S.H. Subclinical atrial fibrillation and the risk of stroke // N. Engl. J. Med. 2012. V 13. P. 120-129.

69. Herweg B., Barold S.S., Steinberg J.S Continuous Monitoring of Atrial Fibrillation in Heart Failure // Heart Failure Clinics. 2013. V. 9. P. 385-395.

70. Hirsh J., Fuster V., Ansell J., Halperin J.L. American Heart

Association/American College of Cardiology Foundation guide to warfarin therapy // J. Am. Coll. Cardiol. 2003. V 41. P. 633-652.

71. Hohnloser S.H., Kuck K.H., Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial // Lancet. 2000. V 356. P 1789-1794.

72. Hughes M., Lip G.Y Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data // J. Thromb. Haemost. 2008. V. 99. P. 295-304.

73. Hylek E.M., Go A.S., Chang Y., Jensvold N.G., Henault L.E., Selby J.V, Singer D.E. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation // N. Engl. J. Med. 2003. V 349. P. 1019-1026.

74. Israel C.W., Gronefeld G., Ehrlich J.R., Li YG., Hohnloser H. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care // J. Am. Coll. Cardiol. 2004. V. 43. P. 47 - 52.

75. Kannel W.B., Abbott R.D., Savage D.D., McNamara P.M. Coronary heart disease and atrial fibrillation: the Framingham Study // Am. Heart J. 1983. V. 106. P. 389-396.

76. Kannel W.B., Abbott R.D., Savage D.D., McNamara P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham study // N. Engl. J. Med. 1982. V. 306. P 1018-1022.

77. Kannel W.B., Benjamin E. Current Perceptions of the Epidemiology of Atrial Fibrillation // Cardiol. Clin. 2009. V. 27. P. 13-24.

78. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease - Framingham Study // J. Am. Med. Assoc. 1979. V 241. P. 2035-2038.

79. Kappenberger. L. A new look at atrial fibrillation: lessons learned from drugs, pacing, and ablation therapies // Eur. Heart J. 2013. V 34. P. 2739-2745.

80. Kerr C., Boone J., Connolly S., Greene M., Klein G., Sheldon R., Talajic M. Follow-up of atrial fibrillation —the initial experience of the Canadian Registry of Atrial Fibrillation // Eur. Heart J. 1996. V 17. Suppl. C. P. 48-51.

81. Kirchhof P, Auricchio A., Bax J., Crijns H., Camm J., Diener H.-C., Goette A., Hindricks G., Hohnloser S., Kappenberger L., Kuck K.-H., Lip G. YH., Olsson B., Meinertz T., Priori S., Ravens U., Steinbeck G., Svernhage E., Tijssen J., Vincent A. Breithardt G. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA) // Eur. Heart J. 2007. V. 28. P. 2803-2817.

82. Kirchhof P., Breithardt G., Aliot E., Al Khatib S., Apostolakis S., Auricchio A., Bailleul C., Bax J., Benninger G, Blomstrom-Lundqvist C., Boersma L., Boriani

G. , Brandes A., Brown H., Brueckmann M., Calkins H., Casadei B., Clemens A., Crijns H., Derwand R., Dobrev D., Ezekowitz M., Fetsch T., Gerth A., Gillis A., Gulizia M., Hack G, Haegeli L., Hatem S., Georg Hausler K., Heidbuchel H., Hernandez-Brichis J., Jais P., Kappenberger L., Kautzner J., Kim S., Kuck K.H., Lane D., Leute A., Lewalter T., Meyer R., Mont L., Moses G., Mueller M., Munzel F., Nabauer M., Nielsen J.C., Oeff M., Oto A., Pieske B., Pisters R., Potpara T., Rasmussen L., Ravens U., Reiffel J., Richard-Lordereau I., Schafer

H. , Schotten U., Stegink W., Stein K., Steinbeck G., Szumowski L., Tavazzi L., Themistoclakis S., Thomitzek K., Van Gelder I.C., von Stritzky B., Vincent A., Werring D., Willems S., Lip GY, Camm A.J. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference // Europace. 2013. V. 15. P. 1540-1556.

83. Kistler J.P., Singer D.E., Millenson M.M., Bauer K.A., Gress D.R., Barzegar S., Hughes R.A., Sheehan M.A., Maraventano S.W., Oertel L.B. Effect of low- intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators // Stroke. 1993. V. 24. P. 1360-1365.

84. Knecht S., Oelschlager C., Duning T., Lohmann H., Albers J., Stehling C., Heindel W., Breithardt G, Berger K., Ringelstein E.B., Kirchhof P., Wersching H. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy // Eur. Heart J. 2008. V. 29. P 2125-2132.

85. Kopekcy S.L., Gersh B.J., McGoon M.D., Whisnant J.P., Holmes D.R. Jr., Ilstrup D.M., Frye R.L. The natural history of lone atrial fibrillation: a population­based study over three decades // N. Engl. J. Med. 1987. V. 317. P. 669-674.

86. Krahn A., Manfreda J., Tate R., Mathewson F.A., Cuddy T.E. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba follow-up study // Am. J. Med. 1995. V 98. P 476-484.

87. Lakshminarayan K., Solid C.A., Collins A.J., Anderson D.C., Herzog C.A. Atrial Fibrillation and Stroke in the General Medicare Population: A 10-Year Perspective (1992 to 2002) // Stroke. 2006. V. 37. P. 1969-1974.

88. LeeB. H., Park J.S., Park J.H., Park J.S., Kwak J.J., Hwang E.S., Kim S.K., Choi D.H., Kim YH., Pak H.N. The effect and safety of the Antithrombotic therapies in patients with atrial fibrillation and CHADS score 1 // J. Cardiovasc. Electrophysiol. 2010. V 21. P 501-507.

89. Liao J., Khalid Z., Scallan C., Morillo C., O’Donnell M. Noninvasive cardiac monitoring for detection of paroxysmal atrial fibrillation or flutter alter acute ischemic stroke: a systematic review // Stroke. 2007. V. 38. P. 2935-2940.

90. Lin H.J., Wolf P.A., Benjamin E.J. D’Agostino R.B. Newly Diagnosed Atrial Fibrillation and Acute Stroke : The Framingham Study // Stroke. 1995. V 26. P 1527-1530.

91. Lin Y.C., Win-Kuang S. Epidemiology of atrial fibrillation: A current perspective // Heart Rhythm. 2007. V. 4. P S1 - S6.

92. Lip GY Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis // Thromb. Haemost. 2008. V 100. P 11-13.

93. Lip GY, Edwards S.J. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis // Thromb. Res. 2006. V118. P 321-333.

94. Lip G.Y, Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation // Chest. 2010. V 137. P 263-272.

95. Lloyd-Jones D., Adams R., Carnethon M., De Simone G., Ferguson T.B., Flegal

K., Ford E., Furie K., Go A., Greenlund K., Haase N., Hailpern S., Ho M., Howard V, Kissela B., Kittner S., Lackland D., Lisabeth L., Marelli A., McDermott M., Meigs J., Mozaffarian D., Nichol G, O'Donnell C., Roger V., Rosamond W., Sacco R., Sorlie P., Stafford R., Steinberger J., Thom T., Wasserthiel-Smoller S., Wong N., Wylie-Rosett J., Hong Y. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee // Circulation. 2009. V. 119. P 480-486

96. Loh E., Sutton M.S.J., Wun C.C.C., Rouleau J.L., Flaker G.C., Gottlieb S.S., Lamas GA., Moye L.A., Goldhaber S.Z., Pfeffer M.A. Ventricular dysfunction and the risk of stroke after myocardial infarction // N. Engl. J. Med. 1997. V. 336 P 251-257.

97. Man J.P., Kapa S., Dixit S. Remote Monitoring for Atrial Fibrillation // Card. Electrophysiol. Clin. 2013. V. 5. P. 357-364.

98. Mann K.G., Brummel K., Butenas S. What is all that thrombin for? // J. Thromb. Haemost. 2003. V. 1. P 1501-1514.

99. Marder VJ., Chute D.J., Starkman S., Abolian A.M., Kidwell C., Liebeskind D., Ovbiagele B., Vinuela F., Duckwiler G, Jahan R., Vespa P.M., Selco S., Rajajee V., Kim D., Sanossian N., Saver J.L. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke // Stroke. 2006. V. 37. P. 2086­2093.

100. Marini C., De Santis F., Sacco S., Russo T., Olivieri L., Totaro R., Carolei A. Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke: Results From a Population-Based Study // Stroke. 2005. V. 36. P. 1115-1119.

101. Marinigh R., Lip G.Y., Lane D.A. Stroke prevention in atrial fibrillation patients // Expert Opin. Pharmacother. 2010. V 11. P. 2331-2350.

102. Matsumoto N., Whisnant J.P., Kurland L.T., Okazaki H. Natural history of stroke in Rochester, Minnesota, 1955 through 1969: an extension of a previous study, 1945 through 1954 // Stroke. 1973. V. 4. P. 20-29.

103. Miyasaka Y, Barnes M.E., Gersh B.J., Cha S.S., Bailey K.R., Abhayaranta W.P., Seward J.B., Tsang T.S. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence // Circulation. 2006. V. 114. P. 119-125.

104. Momjian-Mayor I., Baron J.C. The pathophysiology of watershed infarction in internal carotid artery disease: review of cerebral perfusion studies // Stroke. 2005. V. 36. P. 567-577.

105. Moulin T., Crepin-Leblond T., Chopard J.L., Bogousslavsky J. Hemorrhagic infarcts // Eur. Neurol. 1994. V. 34. P. 64-77.

106. Nabauer M., Gerth A., Limbourg T., Schneider S., Oeff M., Kirchhof P., Goette A., Lewalter T., Ravens U., Meinertz T., Breithardt G, Steinbeck G. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management // Europace. 2009. V. 11. P. 423-434.

107. Nieuwlaat R., Capucci A., Camm A.J., Olsson S.B., Andresen D., Davies D.W., Cobbe S., Breithardt G., Le Heuzey J.Y, Prins M.H., Levy S., Crijns H.J. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation // Eur. Heart J. 2005. V 26. P. 2422-2434.

108. Nishiuma S., Kairo K., Yakushijin K. Genetic variation in the promoter region of the beta-fibrinogen gene is associated with isehemic stroke in a Japanese population // Blood Coagul. Fibrinolysis. 1998. V. 9. P. 373-379.

109. O’Donnell M.J., Xavier D., Liu L., Zhang H., Chin S.L., Rao-Melacini P., Rangarajan S., Islam S., Pais P., McQueen M.J., Mondo C., Damasceno A., Lopez-Jaramillo P., Hankey GJ., Dans A.L., Yusoff K., Truelsen T., Diener H.C., Sacco R.L., Ryglewicz D., Czlonkowska A., Weimar C., Wang X., Yusuf S. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study // Lancet. 2010. V 376. P. 112-123.

110. Olsson S. B., Ingemansson M. P. Chronic atrial fibrillation-how to best reach a permanent sinus rhythm? // Eur. Heart J. 2000. V. 21. P. 11-12.

111. Page R.L., Wilkinson W.E., Clair W.K., McCarthy E.A., Pritchett E.L.C. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia // Circulation. 1994. V. 89. P. 224-227.

112. Patel M.R., Mahaffey K. W., Garg J., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey GJ., Piccini J.P., Becker R.C., Nessel C.C., Paolini J.F., Berkowitz S.D., Fox K.A., Califf R.M. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011. V 365. P. 883-891.

113. Pedersen O.D., Bagger H., K0ber L., Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evaluation // Eur. Heart J.

1999. V. 20. P. 748-754.

114. Penado S., Cano M., Acha O., Hernandez J.L., Riancho J.A. Atrial Fibrillation as a risk factor for stroke recurrence // Am. J. Med. 2003. V 114. P 206-210.

115. Petersen P., Godtfredson J. Embolic complications in paroxysmal atrial fibrillation // Stroke. 1986. V. 17. P. 622-626.

116. Pisters R., Van Oostenbrugge R.J., Knottnerus I.L., de Vos C.B., Boreas A., Lodder J., Prins M.H., Crijns H.J., Tieleman R.G The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines // Europace. 2010. V. 12. P. 779-784.

117. Ridjab D.A., Wittchen F., Tschishow W., Buddecke J., Lamp B., Manegold J., Schabitz W.R., Israel C.W Cor triatriatum sinister and cryptogenic stroke // Herz. 2013, in press.

118. Roger VL., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., Carnethon M.R., Dai S., de Simone G, Ford E.S., Fox C.S., Fullerton H.J., Gillespie C., Greenlund K.J., Hailpern S.M., Heit J.A., Ho P.M., Howard VJ., Kissela B.M., Kittner S.J., Lackland D.T., Lichtman J.H., Lisabeth L.D., Makuc D.M., Marcus GM., Marelli A., Matchar D.B,. McDermott M.M., Meigs J.B., Moy C.S., Mozaffarian D., Mussolino M.E., Nichol G., Paynter N.P., Rosamond W.D., Sorlie P.D., Stafford R.S., Turan T.N., Turner M.B., Wong N.D., Wylie- Rosett J. Heart disease and stroke statistics-2011 update: a report from the American Heart Association // Circulation. 2011. V 123. P e18-e209.

119. Rothwell P.M., Coull A.J., Silver L.E., Fairhead J.F., Giles M.F., Lovelock C.E., Redgrave J.N., Bull L.M., Welch S.J., Cuthbertson F.C., Binney L.E., Gutnikov S.A., Anslow P., Banning A.P., Mant D., Mehta Z. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study) // Lancet. 2005. V 366. P. 1773­1783.

120. Rothwell P.M., Giles M.F., Chandratheva A., Marquardt L., Geraghty O., Redgrave J.N., Lovelock C.E., Binney L.E., Bull L.M., Cuthbertson F.C., Welch S.J., Bosch S., Alexander F.C., Silver L.E., Gutnikov S.A., Mehta Z. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison // Lancet. 2007. V 370. P 1432-1442.

121. Sabatini T., Frisoni G.B., Barbisoni P., Bellelli G., Rozzini R., Trabucchi M. Atrial fibrillation and cognitive disorders in older people // J. Am. Geriatr. Soc.

2000. V. 48. P. 387-390.

122. Savelieva I., John Camm A.J. Atrial fibrillation and heart failure: natural history and pharmacological treatment // Europace. 2003. V 5. Suppl. 1. P S5-S19.

123. Schmitt J., Duray G., Gersh B.J., Hohnloser S.H. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications // Eur. Heart J. 2009. V. 30. P. 1038-1045.

124. Schwarz U.I., Ritchie M.D., Bradford Y, Li C., Frye-Anderson A., Kim R.B., Roden D.M., Stein C.M. Genetic determinants of response to warfarin during initial anticoagulation // N. Engl. J. Med.2008. V 358. P. 999-1008.

125. Seet R.C.S., Rabinstein A.A. Prolonged Rhythm Monitoring in the Patient with Stroke and Transient Ischemic Attack // Card. Electrophysiol. Clin. 2013. V 5. P. 349-356.

126. Sherman D.G, Kim S.G., Boop B.S., Corley S.D., Dimarco J.P., Hart R.G., Haywood L.J., Hoyte K., Kaufman E.S., Kim M.H., Nasco E., Waldo A.L. Occurrence and Characteristics of Stroke Events in the Atrial Fibrillation Follow­up Investigation of Sinus Rhythm Management (AFFIRM) Study // Arch. Intern. Med. 2005. V 165. P 1185-1191.

127. Singer D., Albers G, Dalen J., Fang M.C., Go A.S., Halperin J.L., Lip G.Y., Manning W.J. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines // Chest. 2008. V. 133. P. 546S-592S.

128. Sinha A.M., Diener H.C., Morillo C.A., Sanna T., Bernstein R.A., Di Lazzaro V, Passman R., Beckers F., Brachmann J. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale // Am. Heart J. 2010. V 160. P. 36-41.

129. Somerfield J., Barber A., Anderson N.E., Kumar A., Spriggs D., Charleston A., Bennett P., Baker Y, Ross L. Not all patients with atrial fibrillation-associated ischemic stroke can be started on anticoagulant therapy // Stroke. 2006. V. 37. P. 1217-1220.

130. Sposato L.A., Klein F.R., Jauregui A., Ferrua M., Klin P., Zamora R., Riccio P.M., Rabinstein A. Newly diagnosed atrial fibrillation alter acute ischemic stroke and transient ischemic attack: importance of immediate and prolonged continuous cardiac monitoring // J. Stroke Cerebrovasc. Dis. 2012. V. 21. P. 210-216.

131. Steg P.G., Alam S., Chiang C.E., Gamra H., Goethals M., Inoue H., Krapf L., Lewalter T., Merioua I., Murin J. Naditch-Brule L., Ponikowski P., Rosenqvist M., Silva-Cardoso J., Zharinov O., Brette S., Neill J.O. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry // Heart. 2011. V 98. P 195-201

132. Stewart S., Hart C.L., Hole D.J., McMurray J.J. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study // Am. J. Med. 2002. V. 113. P. 359-364.

133. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial // Lancet. 1996. V 348. P. 633-638.

134. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final results // Circulation. 1991. V. 84. P. 527-539.

135. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study // Lancet. 1994. V 343. P. 687-691.

136. Strong K., Mathers C., Bonita R. Preventing stroke: saving lives around the world // Lancet Neurol. 2007. V. 6. P. 182-187.

137. Thrall G., Lane D., Carroll D., Lip G.Y Quality of life in patients with atrial fibrillation: a systematic review // Am. J. Med. 2006. V. 119. P. e1-e19.

138. Van Gelder I.C., Van Veldhuisen D.J., Lip. GYH. New oral anticoagulants in heart failure // Eur. J. Heart Fail. V. 15. P. 966-973.

139. Vermeer S.E., Longstreth W.T.Jr., Koudstaal PJ. Silent brain infarcts: a systematic review // Lancet Neurol. 2007. V. 6. P. 611-619.

140. Vermeer S.E., Prins N.D., den Heijer T., Hofman A., Koudstal P.J., Berteler M.M. Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline // N. Engl. J. Med. 2003. V 348. P 1215-1222.

141. Waldo A.L. Anticoagulation: Stroke Prevention in Patients with Atrial Fibrillation // Med. Clin. North. Am. 2008. V. 92. P. 143-159.

142. Weir N.U. An update on cardioembolic stroke // Postgrad. Med. J. 2008. V 84. P. 133-142.

143. Welles C.C., Whooley M.A., Na B., Ganz P., Schiller N.B., Turakhia M.P. The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: Data from the Heart and Soul Study // Am. Heart J. 2011. V 163. P. 555-561.

144. Witt B.J Brown R.D.Jr., Jacobsen S.J., Weston S.A., Yawn B.P., Roger VL. A community-based study of stroke incidence after myocardial infarction // Ann. Intern. Med. 2005. V 143. P. 785-792.

145. Wong C.K., White H.D,. Wilcox R.G., Criger D.A., Califf R.M., Topol E.J., Ohman E.M. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience // Am. Heart J. 2000. V 140. P. 878-885.

146. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators // N. Engl. J. Med. 2000. V 342. P. 145-153.